The Supreme Industries Limited (NSE:SUPREMEIND)
India · Delayed Price · Currency is INR 4,249.10
-57.80 (-1.34%)
Aug 1, 2025, 3:30 PM IST
Inozyme Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Revenue | 104,191 | 104,463 | 101,343 | 92,016 | 77,728 | 63,552 | Upgrade |
Revenue Growth (YoY) | 0.16% | 3.08% | 10.14% | 18.38% | 22.31% | 15.31% | Upgrade |
Cost of Revenue | 71,959 | 72,022 | 69,105 | 66,402 | 53,903 | 40,710 | Upgrade |
Gross Profit | 32,232 | 32,441 | 32,237 | 25,614 | 23,825 | 22,842 | Upgrade |
Selling, General & Admin | 6,270 | 6,133 | 5,837 | 4,728 | 4,084 | 3,655 | Upgrade |
Other Operating Expenses | 12,135 | 11,795 | 10,805 | 8,727 | 7,180 | 6,324 | Upgrade |
Operating Expenses | 22,061 | 21,515 | 19,626 | 16,088 | 13,559 | 12,107 | Upgrade |
Operating Income | 10,172 | 10,926 | 12,611 | 9,525 | 10,266 | 10,735 | Upgrade |
Interest Expense | -56.6 | -62.2 | -121.9 | -65.4 | -40.6 | -208.1 | Upgrade |
Interest & Investment Income | 35.1 | 35.1 | 146.3 | 24.3 | 13.6 | 28 | Upgrade |
Earnings From Equity Investments | 1,077 | 1,201 | 1,069 | 1,533 | 2,044 | 1,461 | Upgrade |
Currency Exchange Gain (Loss) | -195.8 | -195.8 | -121.9 | -162.5 | -140.1 | -17.9 | Upgrade |
Other Non Operating Income (Expenses) | -55 | -9.8 | -9 | 6.6 | -2.5 | -7.9 | Upgrade |
EBT Excluding Unusual Items | 10,976 | 11,894 | 13,574 | 10,861 | 12,140 | 11,990 | Upgrade |
Gain (Loss) on Sale of Investments | 484.4 | 484.4 | 476.6 | 234 | 147.7 | 93.8 | Upgrade |
Gain (Loss) on Sale of Assets | 11.9 | 11.9 | 3.7 | 18 | 29.8 | 38.5 | Upgrade |
Pretax Income | 11,473 | 12,390 | 14,054 | 11,113 | 12,318 | 12,122 | Upgrade |
Income Tax Expense | 2,575 | 2,782 | 3,357 | 2,460 | 2,633 | 2,341 | Upgrade |
Net Income | 8,898 | 9,609 | 10,697 | 8,653 | 9,685 | 9,781 | Upgrade |
Net Income to Common | 8,898 | 9,609 | 10,697 | 8,653 | 9,685 | 9,781 | Upgrade |
Net Income Growth | -21.09% | -10.17% | 23.62% | -10.65% | -0.99% | 109.27% | Upgrade |
Shares Outstanding (Basic) | 127 | 127 | 127 | 127 | 127 | 127 | Upgrade |
Shares Outstanding (Diluted) | 127 | 127 | 127 | 127 | 127 | 127 | Upgrade |
EPS (Basic) | 70.05 | 75.64 | 84.21 | 68.12 | 76.24 | 77.00 | Upgrade |
EPS (Diluted) | 70.05 | 75.64 | 84.21 | 68.12 | 76.24 | 77.00 | Upgrade |
EPS Growth | -21.08% | -10.17% | 23.62% | -10.65% | -0.99% | 109.27% | Upgrade |
Free Cash Flow | - | 1,133 | 8,636 | 4,660 | 3.2 | 10,198 | Upgrade |
Free Cash Flow Per Share | - | 8.92 | 67.98 | 36.69 | 0.03 | 80.28 | Upgrade |
Dividend Per Share | - | 34.000 | 30.000 | 26.000 | 24.000 | 22.000 | Upgrade |
Dividend Growth | - | 13.33% | 15.38% | 8.33% | 9.09% | 57.14% | Upgrade |
Gross Margin | 30.94% | 31.05% | 31.81% | 27.84% | 30.65% | 35.94% | Upgrade |
Operating Margin | 9.76% | 10.46% | 12.44% | 10.35% | 13.21% | 16.89% | Upgrade |
Profit Margin | 8.54% | 9.20% | 10.55% | 9.40% | 12.46% | 15.39% | Upgrade |
Free Cash Flow Margin | - | 1.08% | 8.52% | 5.06% | 0.00% | 16.05% | Upgrade |
EBITDA | 13,707 | 14,316 | 15,422 | 11,970 | 12,397 | 12,705 | Upgrade |
EBITDA Margin | 13.15% | 13.71% | 15.22% | 13.01% | 15.95% | 19.99% | Upgrade |
D&A For EBITDA | 3,535 | 3,390 | 2,810 | 2,445 | 2,131 | 1,971 | Upgrade |
EBIT | 10,172 | 10,926 | 12,611 | 9,525 | 10,266 | 10,735 | Upgrade |
EBIT Margin | 9.76% | 10.46% | 12.44% | 10.35% | 13.21% | 16.89% | Upgrade |
Effective Tax Rate | 22.44% | 22.45% | 23.88% | 22.13% | 21.38% | 19.31% | Upgrade |
Revenue as Reported | - | - | - | - | 77,928 | 63,721 | Upgrade |
Advertising Expenses | - | 1,260 | 1,416 | 980.1 | 631.2 | 551.4 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.